Comparative Pharmacology
Head-to-head clinical analysis: BRETHINE versus PROVENTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHINE versus PROVENTIL.
BRETHINE vs PROVENTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing intracellular cAMP, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP
5 mg orally three times daily; may increase to 10 mg if needed; maximum 20 mg daily. Subcutaneous: 0.25 mg, may repeat once in 15-30 minutes (not to exceed 0.5 mg in 4 hours).
Inhalation: 2 inhalations (90 mcg each) every 4-6 hours as needed; oral: 2-4 mg three to four times daily; extended-release: 4-8 mg every 12 hours.
None Documented
None Documented
3-8 hours (terminal); shorter in children and smokers; prolonged in hepatic impairment
Terminal elimination half-life: 3.8–6 hours (inhalation), 3.7–7.1 hours (oral); clinical context: supports dosing every 4–6 hours as needed.
Renal: 50-60% as unchanged drug and metabolites; biliary/fecal: 20-30%
Renal: ~90% (mostly as sulfate conjugates after oral administration, unchanged drug after inhalation); biliary/fecal: <10%.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist